Beyfortus® Immunization: Protecting Infants from RSV
Alpha InspirationMonday, Oct 28, 2024 6:03 pm ET
1min readThe recent approval and distribution of Beyfortus® (nirsevimab-alip) 50mg and 100mg Injection doses in the US marks a significant milestone in the prevention of respiratory syncytial virus (RSV) disease in infants. Sanofi, in collaboration with AstraZeneca, has taken steps to ensure the majority of doses are available ahead of the RSV season, aiming to provide access to immunization for every eligible baby.
RSV is a highly contagious virus that can lead to serious respiratory illness for infants. Two out of three infants are infected with RSV during their first year of life, and almost all children are infected by their second birthday. Most of the time, RSV will cause a mild, cold-like illness. However, in some cases, it can lead to severe lower respiratory tract disease, requiring hospitalization. Beyfortus® is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
The approval of Beyfortus® by the U.S. Food and Drug Administration (FDA) expands manufacturing capacity and helps meet demand. With the recent approval of a new filling line for Beyfortus®, doses are now ready to ship, expanding supply for the Northern Hemisphere ahead of the 2024/2025 RSV season (November – March). Another filling line is expected to provide doses for the 2024/2025 season, adding additional production capacity. Sanofi continues to work with AstraZeneca to build inventory for this and future seasons.
Sanofi also took additional measures to ensure greater readiness for this season by launching the Beyfortus® Reservation Program, which provides critical insight on private healthcare provider demand and allows for prioritized fulfillment of requests placed through the program. The company also continues to collaborate with government agencies, including the White House's Office of Pandemic Preparedness and Response Policy, to ensure readiness.
Private customers interested in ordering Beyfortus® doses should contact their Sanofi representative or request a representative at BEYFORTUS.com.
The approval and distribution of Beyfortus® highlight the commitment of Sanofi and AstraZeneca to protect infants from RSV disease. With the upcoming RSV season, Beyfortus® offers its demonstrated real-world protection to as many infants as possible, contributing to the goal of equitable access to immunization.
RSV is a highly contagious virus that can lead to serious respiratory illness for infants. Two out of three infants are infected with RSV during their first year of life, and almost all children are infected by their second birthday. Most of the time, RSV will cause a mild, cold-like illness. However, in some cases, it can lead to severe lower respiratory tract disease, requiring hospitalization. Beyfortus® is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
The approval of Beyfortus® by the U.S. Food and Drug Administration (FDA) expands manufacturing capacity and helps meet demand. With the recent approval of a new filling line for Beyfortus®, doses are now ready to ship, expanding supply for the Northern Hemisphere ahead of the 2024/2025 RSV season (November – March). Another filling line is expected to provide doses for the 2024/2025 season, adding additional production capacity. Sanofi continues to work with AstraZeneca to build inventory for this and future seasons.
Sanofi also took additional measures to ensure greater readiness for this season by launching the Beyfortus® Reservation Program, which provides critical insight on private healthcare provider demand and allows for prioritized fulfillment of requests placed through the program. The company also continues to collaborate with government agencies, including the White House's Office of Pandemic Preparedness and Response Policy, to ensure readiness.
Private customers interested in ordering Beyfortus® doses should contact their Sanofi representative or request a representative at BEYFORTUS.com.
The approval and distribution of Beyfortus® highlight the commitment of Sanofi and AstraZeneca to protect infants from RSV disease. With the upcoming RSV season, Beyfortus® offers its demonstrated real-world protection to as many infants as possible, contributing to the goal of equitable access to immunization.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet